Emerging antimicrobial platform Anexigen offers a novel SLAY platform for rapid screening of DNA-encoded peptide libraries against Gram-negative pathogens, presenting a unique entry point for collaborations or licensing with pharma and biotech firms seeking next-generation antibiotics.

Targeted collaboration potential With a focus on drug-resistant bacteria and novel antibacterial scaffolds, there are opportunities to partner on preclinical discovery programs, joint ventures, or milestone-based deals with larger pharmaceutical companies looking to augment their antimicrobial pipelines.

Small team agility Operating with a lean team suggests flexibility and speed in negotiations and pilot projects; this can be attractive for strategic partnerships, sponsored research, or contract development and testing arrangements.

Privileged market need The addressable crisis around antimicrobial resistance and the high societal cost creates a favorable narrative for grant-funded programs, academic collaborations, and public-private funding opportunities to de-risk early-stage discovery.

Digital presence leverage Leveraging a modern tech stack and online channels, Anexigen can be positioned for digital outreach, targeted content marketing, and inbound interest from potential collaborators in biotech, pharma, and contract research organizations.